Palizumab and SOX chemo after gastric cancer surgery
Part of Cancer, Digestive system clinical trials.
This trial tests adding palizumab (an immunotherapy) to standard SOX chemotherapy after surgery for stage IIIB-IIIC gastric or GEJ cancer. It's for people whose tumors have certain markers (MSI-H, TMB-H, or high PD-L1) that may make immunotherapy more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You had surgery for stage IIIB-IIIC gastric or gastroesophageal junction cancer
- Your tumor has at least one of these markers: high microsatellite instability (MSI-H), high tumor mutational burden (TMB-H, ≥10 mutations per million DNA letters), or high PD-L1 expression (CPS score ≥5)
- You have not had immunotherapy before
- You are willing to provide a tumor tissue sample from your surgery for testing
- You have good organ function, including normal blood counts and liver/kidney tests
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether adding nivolumab to standard chemotherapy (SOX) given before and around surgery can improve outcomes for people with certain stomach or stomach–esophagus junction cancers. It aims to shrink or control the cancer and make surgery more effective.
This trial tests whether adding a drug called tislelizumab (an immunotherapy) to standard chemotherapy before and after surgery is better than chemotherapy alone for people with a specific type of stomach or GEJ cancer that has a high level of a marker called MHC class II. The goal is to see if it helps shrink the tumor and improves the chance of successful surgery.
This trial tests a new combination of drugs (QL1706 plus chemotherapy SOX) given before and after surgery for stomach or gastroesophageal junction cancer. It aims to shrink the tumor before surgery and help prevent recurrence afterward.
This trial tests whether adding an immunotherapy drug (tislelizumab) to standard chemotherapy before and after surgery can help treat stomach or gastroesophageal junction cancer. It is for people whose cancer has not spread to other organs and who are well enough to have surgery.
This trial tests whether adding immunotherapy to standard chemotherapy after surgery helps prevent stomach or gastroesophageal junction cancer from coming back. It is for people who already had chemotherapy before surgery and have HER2-negative adenocarcinoma.
This trial tests whether adding immunotherapy to standard chemotherapy after surgery can help prevent stomach or gastroesophageal junction cancer from coming back. It is for people whose cancer has been fully removed and who need further treatment.
Hear when a new Gastric Cancer Stage IIIB-IIIC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.